Featured Research

from universities, journals, and other organizations

Protein 'Key' Could Aid Search For Cancer Drugs

Date:
December 16, 2004
Source:
Rice University
Summary:
New research at Rice University is allowing biochemists to understand a key hierarchy of protein interactions that occurs in DNA replication, showing for the first time how a key protein "trumps" its rivals and shuts down cell division while DNA repairs take place.

HOUSTON, Dec. 7, 2004 -- New research at Rice University is allowing biochemists to understand a key hierarchy of protein interactions that occurs in DNA replication, showing for the first time how a key protein "trumps" its rivals and shuts down cell division while DNA repairs take place.

The work, sponsored by the American Cancer Society, appears in the Dec. 8 issue of the journal Structure. It could aid drug makers in designing targeted therapies that block cancer cells from multiplying.

"All cancers are marked by some form of DNA replication gone awry, so a basic understanding of DNA replication is of paramount importance to those designing cancer-fighting drugs," said lead author Yousif Shamoo, assistant professor of biochemistry and cell biology. "In addition, almost every form of life – including bacteria – use a variant of the protein that we studied, and we believe the work may also aid drug makers who are developing new forms of antibiotics."

In the study, Shamoo and graduate student John Bruning used x-ray crystallography and isothermal titration calorimetry to determine the structures of two variants of a protein called Human Proliferating Cellular Nuclear Antigen, or PCNA.

PCNA is a member of the "sliding clamp" family of proteins, which are so-named because of their unique shape and function. Sliding clamps are ring-shaped proteins that slide along strands of DNA. DNA is fed through the hole in the center, and the PCNA acts as a docking mechanism for other proteins that need to interact with the DNA to make repairs or copies or to take part in other genetically regulated tasks. Genes that code for sliding clamp proteins are present in all forms of life except for some viruses.

In humans, at least a dozen proteins are known to dock with PCNA. Each of them docks with PCNA by inserting a kind of key known as a PCNA-interacting protein, or "PIP-box," which binds chemically to the PCNA and holds the docked protein on the DNA strand.

"Each protein that binds with PCNA has its own version of the key, but all the keys fit into the same lock," said Shamoo. "There is a hierarchy among the PIP-box proteins, with some winning out and trumping others before they get a chance to bind. By deciphering the structure of two of these keys, while they were in the lock, we were able to determine their binding energies and find out how the strongest key -- the trump card -- blocks the others and shuts down DNA replication."

The structure of PCNA containing the trump key, the PIP-box from a cell regulatory protein called p21, was solved by researchers at the Rockefeller University. P21 is important because it is produced by cells with damaged DNA. In healthy cells, p21 binds strongly with PCNA to prevent the cells from making copies of DNA until the genetic damage is repaired.

Shamoo and Bruning solved the structure of PCNA containing two other forms of PIP-box keys, both of which are involved in DNA replication. By comparing the chemical structure of the weaker keys against the stronger p21 key, they were able to determine how p21 optimizes its connection to PCNA.

If drug makers can replicate p21's strategy in targeted cancer-fighting compounds, they could attack cancer cells' ability to reproduce at the most basic level.

"The sliding clamp protein that's used by bacteria has the same function as PCNA in humans, but the keys for bacteria are very different from those in humans," said Bruning. "If bacteria use a similar hierarchy to access to their PCNA, it might be possible to design an antibiotic that plays the bacterial trump card without affecting human cells at all."

###

The research was funded by the American Cancer Society, the Welch Foundation and the Houston Area Molecular Biophysics Program.


Story Source:

The above story is based on materials provided by Rice University. Note: Materials may be edited for content and length.


Cite This Page:

Rice University. "Protein 'Key' Could Aid Search For Cancer Drugs." ScienceDaily. ScienceDaily, 16 December 2004. <www.sciencedaily.com/releases/2004/12/041208083014.htm>.
Rice University. (2004, December 16). Protein 'Key' Could Aid Search For Cancer Drugs. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/12/041208083014.htm
Rice University. "Protein 'Key' Could Aid Search For Cancer Drugs." ScienceDaily. www.sciencedaily.com/releases/2004/12/041208083014.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins